Scarica l'app Stockscreener
13.35
0.68%
0.09
Dopo l'orario di chiusura:
13.27
-0.08
-0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$13.26
Aprire:
$13.29
Volume 24 ore:
7.24M
Relative Volume:
0.83
Capitalizzazione di mercato:
$3.51B
Reddito:
$6.16B
Utile/perdita netta:
$246.00M
Rapporto P/E:
14.30
EPS:
0.9333
Flusso di cassa netto:
$508.00M
1 W Prestazione:
+0.23%
1M Prestazione:
+109.91%
6M Prestazione:
+109.25%
1 anno Prestazione:
+53.10%
Intervallo 1D:
$13.27
$13.35
Intervallo di 1 settimana:
$13.25
$13.39
Portata 52W:
$5.69
$13.39
Organon Co Stock (OGN) Company Profile
Nome
Organon Co
Settore
Industria
Telefono
551-430-6000
Indirizzo
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.35 | 3.48B | 6.16B | 246.00M | 508.00M | 0.9333 |
LLY
Lilly Eli Co
|
988.87 | 863.14B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.55 | 539.70B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.11 | 368.19B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
181.24 | 284.52B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.15 | 279.37B | 65.59B | 8.93B | 12.36B | 3.5532 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-10-27 | Downgrade | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Downgrade | Goldman | Buy → Neutral |
| 2023-09-21 | Iniziato | Barclays | Overweight |
| 2023-03-16 | Iniziato | Raymond James | Outperform |
| 2022-10-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Iniziato | Piper Sandler | Neutral |
| 2021-09-01 | Iniziato | BofA Securities | Buy |
| 2021-07-22 | Iniziato | Citigroup | Buy |
| 2021-06-15 | Iniziato | JP Morgan | Neutral |
| 2021-06-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Organon Co Borsa (OGN) Ultime notizie
Sun Pharma Evaluates Financing Plans for $12 Billion Organon Deal Acquisition - Siliconindia
Sun Pharma explores funding mix for $12 billion Organon deal - The Economic Times
Sun Pharma Explores Funding Mix for $12 Billion Organon Deal - Bloomberg
Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Sun Pharma to acquire Organon in $11.75 billion all-cash deal - MSN
Shanghvi’s audacious bet with $11.75-billion Sun-Organon deal - Fortune India
Sun Pharma to acquire Organon for $11.75bn - MSN
Sun Pharma Organon Deal: Indian Pharma King Ne Kar Liya $11.75B Ka Acquisition! Par Debt Ka Risk Kitna? - Whalesbook
A $12 billion US deal pushes Sun Pharma into big leagues - Moneycontrol.com
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? - marketscreener.com
Organon & Co. Reports Q1 2026 Financial Results: Revenue, Net Income, and Key Disclosures from Latest 10-Q Filing - Minichart
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Why Organon will need Dilip Shanghvi’s masterstroke - The Economic Times
Organon & Co. 1Q 2026: Revenue $1.46B, EPS $0.55— 10-Q Summary - TradingView
Sun Pharma to acquire Organon (NYSE: OGN) for $14 per share in cash - Stock Titan
Organon & Co is the best performing healthcare stock in April (XLV:NYSEARCA) - Seeking Alpha
Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more - MSN
India's biggest pharma deal: Sun Pharma to acquire US-based Organon in $11.75 billion deal - Business Standard
Organon stock surges 31% on sweetened $13 billion takeover offer from Sun Pharma - MSN
Sun Pharma's $11.75B Organon Buy: Speciality Drugs, Global Expansion & More - Deccan Herald
India’s Sun Pharma plots $12 billion Organon buyout for global reach - MSN
Sun Pharma exploring Eurobonds, bond swaps to fund US-based Organon buy - Business Standard
Sun Pharma to buy Organon in $11.75B deal, expanding global reach - MSN
Mitsubishi UFJ Trust & Banking Corp Sells 202,370 Shares of Organon & Co. $OGN - MarketBeat
Sun Pharma shares jump 9% as $11.75‑billion Organon buy seals entry into biosimilars, deal expected to close in 2027 - MSN
Sun Pharma shares jump 7% as India's largest drugmaker to buy US firm Organon in $11.75 billion deal - MSN
Organon Buyout And POHERDY Approval Shape Returns And Valuation Outlook - simplywall.st
MSN Money - MSN
Organon jumps 15% as Sun Pharma agrees $11.8bn buyout - MSN
The Sun Pharma-Organon deal, UAE’s divorce from OPEC, and more… - Finshots
Sun Pharma is marrying Organon - Finshots
Organon & Co. (NYSE:OGN) Short Interest Update - MarketBeat
Organon (OGN)’s Investors React Strongly as Sun Pharma Bets Big on Specialty Drug Expansion - Insider Monkey
OGN News Today | Why did Organon & Co. stock go up today? $OGN - MarketBeat
Sun Pharma to acquire Organon for Inorganic Growth - The Financial World
Organon & Co To Go Ex-Dividend On May 11th, 2026 With 0.02 USD Dividend Per Share - Moomoo
Organon (OGN) Margin Hit To 3% Tests Bullish Earnings Recovery Story - simplywall.st
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates - StockStory
Organon & Co. (NYSE:OGN) Declares $0.02 Quarterly Dividend - MarketBeat
Sun Pharma To Acquire Former Merck Spinoff, Organon for $11.75 Bn - DCAT Value Chain Insights
Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry - Insider Monkey
Vanguard Capital Management reports 13.7M shares in Organon (OGN) - Stock Titan
Organon Reports Results for the First Quarter Ended March 31, 2026 - BioSpace
Sun Pharma’s $11.75 billion Organon deal: not all brokers are hailing the high ROCE swap for leverage - Moneycontrol.com
Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Organon (OGN) Q1 Earnings and Revenues Miss Estimates - Yahoo Finance
India's Sun Pharma to buy US-listed Organon in about $11.8 billion deal - MSN
Earnings Flash (OGN) Organon & Co. Reports Q1 Revenue $1.46B, vs. FactSet Est of $1.49B - marketscreener.com
Earnings Flash (OGN) Organon & Co. Posts Q1 Adjusted EPS $0.71 per Share, vs. FactSet Est of $0.83 - marketscreener.com
Organon Co Azioni (OGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):